# ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

> **NCT04121507** · PHASE2 · COMPLETED · sponsor: **GWT-TUD GmbH** · enrollment: 60 (actual)

## Conditions studied

- Aggressive Non-hodgkin Lymphoma (aNHL)
- Lymphoma, B-Cell
- Lymphoma, T-Cell

## Interventions

- **DRUG:** High dose chemotherapy before allogeneic stem cell transplantation (alloSCT)
- **PROCEDURE:** Bone marrow histology
- **DIAGNOSTIC_TEST:** clinical and laboratory parameters
- **DIAGNOSTIC_TEST:** PET-CT or CT

## Key facts

- **NCT ID:** NCT04121507
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-24
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-02-02
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2023-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04121507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04121507, "ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04121507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*